News
SIBN
--
0.00%
--
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Checks have BofA staying bullish on medtech names as demand shores up
A couple of weeks of diligence calls has led to an update on medical technology from BofA, where it changes a few ratings (mainly on valuation), raises a few price
Seekingalpha · 09/08 23:30
SI-BONE (NASDAQ:SIBN) Shareholders Have Enjoyed A 15% Share Price Gain
On average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
Simply Wall St. · 09/01 13:38
SI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference
SANTA CLARA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare
GlobeNewswire · 09/01 12:30
Moving Average Crossover Alert: SI-BONE
Zacks · 08/26 12:49
SI-BONE shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. Morgan Stanley also maintained an Overweight rating on the stock and raised its price target from $20 to $25 per share.
Benzinga · 08/04 17:06
Did Hedge Funds Make The Right Call On SI-BONE, Inc. (SIBN) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 08/04 14:59
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $25
Morgan Stanley maintains SI-BONE (NASDAQ:SIBN) with a Overweight and raises the price target from $20 to $25.
Benzinga · 08/04 12:42
SI-BONE EPS beats by $0.22, beats on revenue
SI-BONE (NASDAQ:SIBN): Q2 GAAP EPS of -$0.44 beats by $0.22. Revenue of $14.05M (-13.9% Y/Y) beats by $5.27M. Press Release
seekingalpha · 08/04 01:16
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 48.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 23:05
SI-BONE Q2 EPS $(0.44) Beats $(0.64) Estimate, Sales $14.00M Beat $8.29M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.64) by 31.25 percent. This is a 25.71 percent decrease over losses of $(0.35) per share from the same
Benzinga · 08/03 20:27
SI-BONE, Inc. Reports Second Quarter 2020 Financial Results
SANTA CLARA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2020. Recen
GlobeNewswire · 08/03 20:05
SI-BONE to Present at the 40th Annual Canaccord Genuity Growth Conference
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcomin
GlobeNewswire · 07/30 20:09
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
SI-BONE To Report Second Quarter 2020 Financial Results on August 3, 2020
SANTA CLARA, Calif., July 21, 2020 -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today.
GlobeNewswire · 07/21 12:00
Hedge Funds Have Never Been This Bullish On SI-BONE, Inc. (SIBN)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These fi
Insider Monkey · 06/24 03:09
SI-BONE announces $40M debt re-financing
Seeking Alpha - Article · 06/01 18:03
SI-BONE, Inc. Announces $40 Million Debt Re-Financing
GlobeNewswire · 06/01 13:30
SI-BONE, Inc. Announces Aetna Establishes Positive Coverage for MIS SI Joint Fusion using the Triangular iFuse Implant System
SI-BONE, Inc., (SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Aetna has established a positive coverage policy for minimally invasive SI joint fusion. This
GlobeNewswire · 05/29 13:18
Notice of Change of Location of Annual Meeting of Stockholders of SI-BONE, Inc. to Be Held on June 16, 2020
GlobeNewswire · 05/27 21:05
Webull provides a variety of real-time SIBN stock news. You can receive the latest news about SI-BONE through multiple platforms. This information may help you make smarter investment decisions.
About SIBN
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
More